Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the APPL2 siRNA guide strand refer to a collection of unintended transcripts that are silenced during RNA interference (RNAi) experiments or therapies targeting the APPL2 gene (Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2). This phenomenon occurs when the 'seed region' of the siRNA—typically nucleotides 2 through 8—binds to the 3' untranslated regions (UTRs) of non-target mRNAs, triggering their degradation or inhibiting their translation in a manner similar to endogenous microRNAs (Jackson et al., 2003, Nature Biotechnology). APPL2 itself is an important adaptor protein involved in endosomal signaling, insulin sensitivity, and chromatin remodeling (UniProt, Q8NEU8). Because APPL2 is a potential therapeutic target in metabolic and inflammatory diseases, the specificity of its knockdown is critical. Unintended silencing of off-target mRNAs can lead to significant cellular toxicity and misleading phenotypic data, which are major hurdles in the development of siRNA-based therapeutics (Birmingham et al., 2006, Nature Methods). Mitigation strategies include the use of chemical modifications to the siRNA backbone and advanced bioinformatic algorithms to select sequences with minimal transcriptome-wide seed complementarity.
Seed-sequence mediated binding of the siRNA guide strand to the 3' untranslated region (UTR) of non-target mRNAs, leading to RISC-mediated degradation or translational repression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to APPL2 siRNA guide strand.